514 related articles for article (PubMed ID: 10817105)
1. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
[TBL] [Abstract][Full Text] [Related]
2. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
[TBL] [Abstract][Full Text] [Related]
3. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Kavoussi RJ; Segraves RT; Hughes AR; Ascher JA; Johnston JA
J Clin Psychiatry; 1997 Dec; 58(12):532-7. PubMed ID: 9448656
[TBL] [Abstract][Full Text] [Related]
6. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
8. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
Grunebaum MF; Keilp JG; Ellis SP; Sudol K; Bauer N; Burke AK; Oquendo MA; Mann JJ
J Clin Psychiatry; 2013 Sep; 74(9):872-9. PubMed ID: 24107760
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
Croft H; Settle E; Houser T; Batey SR; Donahue RM; Ascher JA
Clin Ther; 1999 Apr; 21(4):643-58. PubMed ID: 10363731
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
[TBL] [Abstract][Full Text] [Related]
11. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.
DeBattista C; Solvason HB; Poirier J; Kendrick E; Schatzberg AF
J Clin Psychopharmacol; 2003 Feb; 23(1):27-30. PubMed ID: 12544372
[TBL] [Abstract][Full Text] [Related]
12. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
13. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
Clayton AH; McGarvey EL; Abouesh AI; Pinkerton RC
J Clin Psychiatry; 2001 Mar; 62(3):185-90. PubMed ID: 11305705
[TBL] [Abstract][Full Text] [Related]
14. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.
Nieuwstraten CE; Dolovich LR
Ann Pharmacother; 2001 Dec; 35(12):1608-13. PubMed ID: 11793630
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine versus placebo: a double-blind comparison in depressed patients.
Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
